Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies

The outcomes of patients with DLBCL and primary treatment failure (PTF) in the rituximab era are unclear. We analyzed 331 patients with PTF, defined as primary progression while on upfront chemoimmunotherapy (PP), residual disease at the end of upfront therapy (RD) or relapse <6 months from end o...

全面介紹

Na minha lista:
書目詳細資料
發表在:Am J Hematol
Main Authors: Costa, Luciano J., Maddocks, Kami, Epperla, Narendranath, Reddy, Nishitha M., Karmali, Reem, Umyarova, Elvira, Bachanova, Veronika, Costa, Cristiana, Glenn, Martha J., Chavez, Julio C., Calzada, Oscar, Lansigan, Frederick, Nasheed, Hossain, Barta, Stefan K., Zhou, Zheng, Jaglal, Michael, Chhabra, Saurabh, Hernandez-Ilizaliturri, Francisco, Xavier, Ana C., Mehta, Amitkumar, Peker, Deniz, Forero-Torres, Andreas, Al-Mansour, Zeina, Evens, Andrew M., Cohen, Jonathon B., Flowers, Christopher R., Fenske, Timothy S., Hamadani, Mehdi
格式: Artigo
語言:Inglês
出版: 2017
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5549936/
https://ncbi.nlm.nih.gov/pubmed/27880984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24615
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍